InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,304.72
(
0.70%
)
US TECH 100
18,318.00
(
0.95%
)
Dow Jones
39,069.59
(
0.01%
)
Brent Oil
82.17
(
0.23%
)
Bitcoin
68,617.50
(
0.16%
)
Post# of 251942
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 829
Posts 119691
Boards Moderated 16
Alias Born 09/05/2002

DewDiligence

Member Level

Re: caravon post# 225266

Friday, 06/14/2019 7:22:00 PM

Friday, June 14, 2019 7:22:00 PM

Post# of 251942

Some...are trying to compare the ENTA—[RSV]—data with the failed JNJ Ph3 trial.

JNJ’s RSV drug, lumicitabine, did not fail in phase-3; rather, the lumicitabine program was terminated during phase-2 due to an undisclosed safety problem:

#msg-144276889
#msg-147714156

https://www.clinicaltrials.gov/ct2/show/NCT02935673
https://www.clinicaltrials.gov/ct2/show/NCT03333317

In short, there is no read-through from JNJ's RSV program to ENTA's.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up